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ABSTRACT: Introduction: Dystrophinopathy is a rare, severe
muscle disorder, and nonsense mutations are found in 13% of
cases. Ataluren was developed to enable ribosomal readthrough
of premature stop codons in nonsense mutation (nm) genetic
disorders. Methods: Randomized, double-blind, placebo-controlled study; males 5 years with nm-dystrophinopathy received
study drug orally 3 times daily, ataluren 10, 10, 20 mg/kg
(N 5 57); ataluren 20, 20, 40 mg/kg (N 5 60); or placebo
(N 5 57) for 48 weeks. The primary endpoint was change in 6Minute Walk Distance (6MWD) at Week 48. Results: Ataluren
was generally well tolerated. The primary endpoint favored ataluren 10, 10, 20 mg/kg versus placebo; the week 48 6MWD
D 5 31.3 meters, post hoc P 5 0.056. Secondary endpoints
(timed function tests) showed meaningful differences between
ataluren 10, 10, 20 mg/kg, and placebo. Conclusions: As the first
investigational new drug targeting the underlying cause of nmdystrophinopathy, ataluren offers promise as a treatment for this
orphan genetic disorder with high unmet medical need.

This is an open access article under the terms of the Creative Commons
Attribution-Non-Commercial-NoDerivs Licence, which permits use and distribution in any medium, provided the original work is properly cited, the
use is non-commercial and no modifications or adaptations are made.
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Approximately 13% of patients with dystrophinopathy have a nonsense mutation in the gene for
dystrophin.1 A nonsense mutation results in a
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premature stop codon within the protein coding
region of the corresponding messenger ribonucleic
acid (mRNA) and causes premature termination of
translation and generation of a truncated, unstable, nonfunctional protein. There are 3 different
types of premature stop codons: opal, amber (uridine-adenosine-guanosine), and ochre (uridineadenosine-adenosine). Nonsense-mediated mRNA
decay (NMD) weakens mRNA, and readthrough of
nonsense mutations allows for production of functional protein by altering the level of mRNA deterioration when readthrough activity is established.2
Readthrough of a premature stop codon is a novel
approach to treat genetic disorders due to a nonsense mutation. Aminoglycoside antibiotics such as
gentamicin have been investigated for their potential ability to promote premature stop codon readthrough in patients with nonsense mutation
dystrophinopathy.2–5 The development of a safe,
orally bioavailable drug that has readthrough activity would be beneficial to Duchenne muscular dystrophy (DMD) patients with nonsense mutations in
their dystrophin gene.4 To treat genetic disorders
due to a nonsense mutation, ataluren (PTC124)
has been developed as a first-in-class, investigational new drug designed to enable ribosomal
readthrough of premature stop codons.
Ataluren’s activity has been demonstrated independently in a large number of peer-reviewed
articles of multiple disease models spanning many
different organ systems, including models of dystrophinopathy.2,3,6–21 A proof-of-concept Phase 2a trial
demonstrated that ataluren produced dystrophin in
patients with nonsense mutation dystrophinopathy.22 A second Phase 2a study demonstrated that
ataluren produced cystic fibrosis transmembrane
conductance regulator (cftr) protein in nonsense
mutation cystic fibrosis patients.23,24
Based on the results of the proof-of-concept clinical trials, we conducted a Phase 2b registrationdirected study. Before this study, very few largescale, randomized, controlled trials had been performed in dystrophinopathy, and none had been
performed using a new chemical entity targeting
the underlying cause of DMD.25 This Phase 2b
study is a randomized, double-blind, placebo-controlled international study that evaluated the efficacy and safety of 2 doses of ataluren in patients
with
nonsense
mutation
dystrophinopathy
(referred to in this study as nonsense mutation
DMD [nmDMD]). This trial in dystrophinopathy
used the 6-Minute Walk Test (6MWT) as an outcome measure. As this was the first study for registration in DMD, there were no established primary
or secondary endpoints from a regulatory perspective, and there was limited DMD natural history
data available at the time the study was designed.
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Completion of this trial has provided a better
understanding of the natural history of DMD using
the 6MWT and has established the 6MWT as a validated primary endpoint in DMD clinical trials; in
addition, the data from this trial have helped to
identify the best secondary endpoints in DMD trials and lay the clinical trial groundwork for future
therapies for this disease.26
MATERIALS AND METHODS
Participants. Patients were enrolled at 37 sites in
11 countries, which featured the following inclusion
criteria: male, 5 years of age with a documented
nonsense mutation in the dystrophin gene, onset of
dystrophinopathy symptoms by age 9 years, elevated
serum creatine kinase (CK), and difficulty ambulating but able to walk 75 meters unassisted during a
6MWT at screening. Stable use of concomitant glucocorticoids was allowed.
At each participating institution, institutional
review boards/ethics committees and health authorities approved the study protocol. All parents/participants provided signed informed consent/assent
before study initiation. The trial was conducted in
accordance with the Declaration of Helsinki and
Good Clinical Practice and was registered (Identifier NCT00592553) at www.clinicaltrials.gov.
Procedures. Patients were stratified prospectively
by age (<9 or 9 years), use of glucocorticoids
(yes or no), and baseline 6-Minute Walk Distance
(6MWD) (350 or <350 meters) and were
randomized 1:1:1 to receive study drug orally 3
times daily for 48 weeks (ataluren 10, 10, 20 mg/
kg, henceforth referred to as ataluren 40 mg/kg/
day; or ataluren 20, 20, 40 mg/kg, referred to as
ataluren 80 mg/kg/day; or placebo). Evaluations
were performed at screening, baseline and every 6
weeks. The primary outcome measure was the
6MWD.27,28 Secondary outcome measures of physical functioning included timed function tests
([TFTs] - stand from supine, 4-stair ascend, 4-stair
descend, and 10 meter run/walk), functional test
method grading, at-home activity, myometry (knee
flexion and extension, elbow flexion and extension, and shoulder abduction), patient/caregiverreported accidental falls, and the Pediatric Quality
of Life Inventory (PedsQL) physical functioning
and psychosocial domains,29 Treatment Satisfaction Questionnaire for Medication (TSQM), verbal
memory and attention, heart rate, and serum CK.
Safety, study drug compliance, and ataluren
plasma concentrations before (C0h) and 2 h (C2h)
following the morning dose30 were evaluated.
Biceps muscle dystrophin expression was also
assessed (fully detailed in Supplementary Appendix – available online). Biopsy of the biceps brachii
was performed at baseline (pretreatment sample)
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and from the contralateral arm at Week 36 6 14
days (posttreatment sample) to assess for production of dystrophin. Biopsies were performed at the
37 study sites in 11 countries (United States,
United Kingdom, Italy, Australia, Germany, Canada, France, Sweden, Spain, Belgium, and Israel).
Samples were shipped to Covance Central Lab and
stored at 280 C.
Statistical Analysis. The study hypothesis was that
mean change in 6MWD from baseline to 48 weeks
would be 30 meters better in at least 1 ataluren
arm versus placebo. Thirty meters was selected
based on the 6MWD treatment effects seen in trials
of drugs which have been approved for the treatment of other rare diseases with neuromuscular
complications.31,32 Based primarily on earlier
observational 6MWD data in DMD patients,27,28 as
well data from other diseases,31,32 the standard
deviation of the change in 6MWD was hypothesized in the protocol to be 50 meters, and this
standard deviation was assumed for sample size
determination. The prespecified intent-to-treat
(ITT) population included all randomized subjects
with a valid 6MWT available at baseline and 1
postbaseline visit. Mixed-model repeated-measures
(MMRM) analyses of changes from baseline to
Week 48 were performed. Terms in the model
included treatment, visit, treatment*visit, and the
stratification factors. Original data were to be analyzed, if the data were normally distributed; otherwise, log-transformed data were to be analyzed, if
the log-transformed data were normally distributed; otherwise, rank-transformed data were to be
analyzed. Shapiro-Wilk testing was used to determine if the data were distributed normally. The
MMRM model fit was improved post hoc by the
addition of a baseline*visit interaction term.33,34
The baseline values for 2 patients (1 placebo-dosed
and 1 treated with ataluren 80 mg/kg) were
replaced by their screening values, because their
baseline 6MWDs were radically lower than their
screening and Week 6 values due to lower-limb
injuries before the baseline test. This is referred to
as the corrected ITT (cITT) population. The post
hoc analysis was performed on the untransformed
data with deviations from assumptions addressed
by means of a re-randomization test (10,000 iterations) using MMRM. Details of prespecified statistical methods and post hoc modifications are
provided in the Supplementary Appendix.
The P-values of the primary and secondary outcome measures were adjusted for comparisons of 2
dose levels against placebo. All analyses were 2sided at the 0.05 level of significance. Where P-values are described as nominal, they are not adjusted
for multiplicity.
Ataluren for Dystrophinopathy

RESULTS
Patient Disposition and Characteristics.

The ITT
population included all 174 randomized patients,
of whom 57 were assigned to placebo, 57 to ataluren 40 mg/kg/day, and 60 to ataluren 80 mg/kg/
day (Supplementary Appendix, which is available
online). One patient discontinued at Week 6 due
to noncompliance. The remaining 173 patients
completed 48 weeks. Patients ranged in age from 5
to 20 years (Table 1). All 3 premature stop codon
types were represented. There was no significant
difference among the 3 arms in any patient
characteristic.
Median study drug compliance was >97%. Ataluren concentrations before and 2 h after the
morning dose were dose-proportional and
remained stable over time.
Seventy-one percent (124/174) of patients were
receiving glucocorticoids, which was equal across
treatment arms, and of these, 92 (74%) received
glucocorticoids daily, 7 (6%) received glucocorticoids every other day, and 25 (20%) were on other
regimens. Changes in glucocorticoid regimens
were minimal during the study. No patients discontinued glucocorticoid use during the study.
Safety. Ataluren was generally well tolerated at
both dose levels (Supplementary Appendix). There
were no study discontinuations due to adverse
events. No ataluren-related serious adverse events
were reported. Most treatment-emergent adverse
events were mild or moderate. Investigator attributions of drug-related adverse effects showed similar
frequencies across the placebo- and atalurentreated arms. Changes in laboratory and physical
parameters generally were not significant clinically.

Primary Endpoint. In the ITT population, mean declines in 6MWD at Week 48 of 42.6
and 12.9 meters were observed for placebo and ataluren 40 mg/kg/day, respectively (D 5 29.7 meters,
nominal P 5 0.149, MMRM on ranks). This difference was consistent with the targeted treatment effect
size of 30 meters. In the corrected ITT population,
mean declines in 6MWD at Week 48 of 44.1 and 12.8
meters were observed for placebo and ataluren
40 mg/kg/day, respectively (see Fig. 1; D 5 31.3
meters, P 5 0.056, re-randomization MMRM adjusted
for multiplicity). The difference in the mean change
in 6MWD from baseline to Week 48 between placebo
and ataluren 80 mg/kg/day was negligible.
Progression of 6MWD was defined a priori based
on time to persistent 10% 6MWD worsening relative to baseline. In the ITT population, 26% of
patients in the ataluren 40 mg/kg/day arm, as
compared with 44% of patients in the placebo
arm, had experienced persistent 10% 6MWD worsening by Week 48. This corresponds to a 48%

Efficacy.
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Table 1. Patient characteristics.
Treatment arm

Characteristic
Demographics
Age, years
Mean (SD)
Median
Range
Race, n (%)
Caucasian
Black
Asian
Hispanic
Other
Body height, cm
Mean (SD)
Median
Range
Body weight, kg
Mean (SD)
Median
Range
Stop codon type, n (%)
UGA
UAG
UAA
Stratification factors
Age group, n (%)
<9 years
9 years
Glucocorticoid use, n (%)
Yes
No
Baseline 6MWD, n (%)
350 m
<350 m
Functional characteristics
6MWD, m, mean (SD)
%-predicted 6MWD, mean (SD)
Climb 4 stairs, s, mean (SD)
Descend 4 stairs, s, mean (SD)
10-m run/walk, s, mean (SD)
Supine to stand, s, mean (SD)
Falls/day*, mean (SD)

Placebo
N557

40 mg/kg/day
N557

80 mg/kg/day
N560

8.3 (2.33)
8.0
5–15

8.8 (2.91)
8.0
5–20

8.4 (2.53)
8.0
5–16

54
0
1
1
1

53
1
1
1
1

50
1
4
2
3

(94.7)
(0.0)
(1.8)
(1.8)
(1.8)

(93.0)
(1.8)
(1.8)
(1.8)
(1.8)

(83.3)
(1.7)
(6.7)
(3.3)
(5.0)

123 (11.8)
122
104–163

125 (15.3)
121
99–173

126 (13.8)
126
99–173

29 (9.1)
26
16–55

31 (12.1)
27
16–76

32 (12.8)
28
17–84

31 (54.4)
12 (21.1)
14 (24.6)

29 (50.9)
17 (29.8)
11 (19.3)

23 (38.3)
19 (31.7)
18 (30.0)

32 (56)
25 (44)

32 (56)
25 (44)

34 (57)
26 (43)

40 (70)
17 (30)

41 (72)
16 (28)

43 (72)
17 (28)

35 (61)
22 (39)

32 (56)
25 (44)

33 (55)
27 (45)

361 (87.5)
61.9 (16.26)
6.0 (5.67)
5.5 (5.75)
6.7 (2.67)
11.5 (11.44)
0.5 (0.94)

350 (97.6)
59.6 (18.06)
6.9 (6.47)
6.1 (5.98)
7.4 (4.37)
10.8 (9.92)
0.3 (0.48)

361 (99.7)
61.6 (17.78)
7.5 (7.46)
6.7 (7.21)
7.4 (4.36)
12.3 (11.19)
0.4 (0.60)

*Baseline falls/day data were available for 48, 48, and 54 patients in the placebo, ataluren 40 mg/kg/day, and ataluren 80 mg/kg/day treatment arms,
respectively.
SD, standard deviation; UAA, uridine-adenosine-adenosine; UAG, uridine-adenosine-guanosine; UGA, uridine-guanosine-adenosine

reduction in the risk of 10% 6MWD worsening
(Figure 2; hazard ratio of ataluren 40 mg/kg/day
vs. placebo of 0.52, nominal P 5 0.039). Similar
results were observed for the corrected ITT population (hazard ratio 5 0.51, nominal P 5 0.033).
The proportion of patients with persistent 10%
6MWD worsening at Week 48 in the ataluren
80 mg/kg/day arm was similar to placebo.
Recently, an age- and height-based equation35
has been used to convert 6MWD to %-predicted
6MWD in patients with DMD,36 which accounts for
maturational differences in 6MWD. This equation
was applied to 6MWD data in the corrected ITT
480
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population. At baseline, this DMD cohort performed the 6MWT at approximately 60% predicted. Mean declines in %-predicted 6MWD at
Week 48 of 7.6% and 2.7% were observed for placebo and ataluren 40 mg/kg/day, respectively
(D 5 4.9%, P 5 0.055, re-randomization MMRM
adjusted for multiplicity). The mean decline for
ataluren 80 mg/kg/day was 7.7%. The significance
level of this %-predicted analysis is consistent with
the results of the analysis of the 6MWD in meters,
in which a P-value of 0.056 was observed.
Age, glucocorticoid use, and baseline 6MWD
were prespecified as stratification factors, because
MUSCLE & NERVE
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FIGURE 3. Mean change in 6MWD from baseline to week 48 in
the < 350 meters 6MWD subgroup.
FIGURE 1. Change in 6MWD. Mean changes in the ataluren
10, 10, 20 mg/kg and placebo arms were 212.86 and 244.14
meters, respectively, resulting in a difference of 31.28 meters.

these variables were likely to have prognostic significance. Analyses of mean changes in 6MWD within
the 6 subgroups defined by the 3 stratification factors showed that all ataluren 40 mg/kg/day subgroups performed better relative to the
corresponding placebo subgroup. The largest
mean differences between ataluren 40 mg/kg/day
and placebo were observed in patients <9 years
old, patients receiving glucocorticoids, and patients
with baseline 6MWD <350 meters.
The natural history of changes in ambulation
as measured by the 6MWT,26 indicates that
patients greater than 350 meters at baseline generally do not demonstrate substantial changes in
their 6MWDs in 48 weeks while those less than 350
meters tend to show large declines. Based on this,
and the fact that a baseline value of 350 meters
was a prespecified stratification factor, an analysis
was performed on the prespecified group with
baseline 6MWD < 350 meters. In this prespecified
subgroup with baseline 6MWD < 350 meters in
patients treated with ataluren 40 mg/kg/day the
mean change of 6MWD from baseline to Week 48
was 68.2 meters better than placebo-dosed patients
(nominal P 5 0.0053, see Figure 3).
Further analysis was performed on patients likely
to be in the ambulatory decline phase of the disease

FIGURE 2. Time to persistent 10% worsening in 6MWD.
Ataluren for Dystrophinopathy

subsequent to age 7. This subgroup consisted of
nmDMD patients aged 7 to 16 with a baseline %predicted 6MWD 80% and, to minimize heterogeneity, who were taking corticosteroids and had a baseline 6MWD 150 meters. In this decline-phase
subgroup, in patients treated with ataluren 40 mg/
kg/day, the mean change of 6MWD from baseline to
Week 48 was 49.9 meters better than placebo-dosed
patients (nominal P 5 0.0096; see Fig. 4). Separation
between ataluren 40 mg/kg/day and placebo in the
decline-phase subgroup occurred early (6 weeks),
and by 24 weeks there was a 30 meter treatment difference between ataluren 40 mg/kg/day in comparison to the placebo group (nominal P 5 0.047).
The baseline characteristics for the declinephase subgroup and the < 350 meters subgroup
were balanced across the 3 treatment arms (see
Table 2).
Although the effect of ataluren was most evident in patients in the ambulatory decline-phase,
the activity of ataluren was seen across the disease
spectrum. As shown in Figure 5, the Phase 2b
patients can be categorized based on %-predicted
6MWD at baseline. All patients, including milder
patients (>70% predicted), showed a favorable
effect for ataluren, and the overall results were not
driven by milder patients.
Secondary Endpoints. In TFTs, ataluren-treated
patients demonstrated smaller increases in the

FIGURE 4. Mean change in 6MWD from baseline to week 48 in
the decline-phase subgroup.
MUSCLE & NERVE
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Table 2. Frequency of patients within levels of stratification
factors.
Parameter

< 9 years
 9 years
< 350 meters baseline
6MWD
 350 meters baseline
6MWD
Corticosteroid use

< 9 years
 9 years
< 350 meters baseline
6MWD
Corticosteroid use
No corticosteroid use

Ataluren
Ataluren
Placebo 40 mg/kg/day 80 mg/kg/day
N531
39%
61%
42%

Decline phase subgroup
N532
N533
41%
36%
59%
64%
44%
42%

58%

56%

58%

100%
100%
100%
< 350 meters 6MWD subgroup
N522
N525
N527
36%
44%
48%
64%
56%
52%
100%
100%
100%
64%
36%

68%
32%

59%
41%

time it takes to climb 4 steps, descend 4 steps, and
run/walk 10 meters relative to placebo (Table 3.).
The log of the threshold for the clinically meaningful difference in TFTs was estimated to be
0.4 s,37 which corresponds to 1.5 s on the
untransformed scale. These trends were more
prominent at the 40 mg/kg/day dose, which meets
the threshold (1.5 s) and suggests clinically
meaningful differences in TFTs.37 Positive trends
for ataluren 40 mg/kg/day were also seen in functional method grading (Table 3.); see detailed
explanation in Supplementary Appendix. Differences between ataluren versus placebo for mean
changes in supine to stand were small for both
dose levels, and at baseline 23% of patients were
unable to stand from supine within the predefined
maximum of 30 seconds (vs. 3% patients in other
TFTs), limiting the ability to demonstrate a treatment effect with this test.

FIGURE 5. Mean change in 6MWD by disease severity.
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Compared with the results of the overall population, in the prespecified baseline 6MWD < 350
meters subgroup, the results favoring ataluren
were even greater in values of 10 meter run/walk
(3.5 s), the time to climb 4 steps (6.4 s), and the
time to descend 4 steps (5.0 s). Also similar to
these results, the ambulatory decline-phase subgroup exhibited greater differences in the TFTs of
4-stair climb, 4-stair descend, and 10-meter run/
walk of ataluren over placebo compared with the
overall study population. In this subgroup,
the results favoring ataluren were nearly twice the
1.5 s clinically meaningful threshold in the 10meter run/walk (2.8 s), the time to climb 4 steps
(2.9 s), and the time to descend 4 steps (2.9 s)
(see Fig. 6).
Positive trends favoring ataluren 40 mg/kg/day
versus placebo were seen in patient-reported physical functioning, as measured by the PedsQL. The
difference in the mean change in physical functioning score was 3.4 at Week 48. This was more
pronounced in the ambulatory decline-phase subgroup with a difference of 6.1 in the mean change
in physical functioning score, favoring ataluren
40 mg/kg/day over placebo at Week 48.
Accidental falling is the most common cause of
limb fractures in boys with DMD,38 and 35 to
40% of lower-limb fractures result in permanent
loss of ambulation.39 This patient-reported outcome was monitored by patient/caregiver diaries.
The results show reductions in accidental falling
for ataluren versus placebo; the relative ratios
of the estimated fall rates at Week 48 were 0.38
(95% CI 5 0.16, 0.94) for ataluren 40 mg/kg/day
versus placebo.
Additional positive trends favoring ataluren
40 mg/kg/day versus placebo were seen across
the other secondary outcome measures of physical functioning, including activity and wheelchair
use in the community setting, as well as myometric evaluation of muscle strength, (see Supplementary Appendix). In 5- to 6-year-old patients
treated with ataluren 40 mg/kg/day, a 30 meter
treatment benefit in 6MWD versus placebo was
seen. In addition, 5- to 6-year-old patients treated
with ataluren 40 mg/kg/day showed stable or
improved TFTs, whereas patients treated with ataluren 80 mg/kg/day or dosed with placebo
showed worsening over 48 weeks. These younger
patients treated with ataluren 40 mg/kg/day also
showed an improvement across all myometry
measures compared with patients dosed with
placebo (For further 5 to 6 year old data, see
Supplementary Appendix). Secondary outcome
measures unrelated to physical functioning did
not show a difference between ataluren and
placebo.
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Table 3.. Timed function test scores (corrected ITT population).
Mean time and change from baseline to week 48 (D) in seconds
Placebo
Endpoint*

Baseline

Climb 4 stairs, s

6.0

40 mg/kg/day ataluren
Week 48

Baseline

10.8

6.9

D54.8
Descend 4 stairs

5.5

9.6

6.8

6.1

9.8

11.4

Baseline

9.3

7.7

8.5

7.4

11.2

6.8

9.7
D53.0

9.1

7.8

10.2

D51.7
14.6

10.8

D53.2

Week 48
D53.5

D52.4

D53.0
Supine to stand

Week 48
D52.4

D54.0
Run/walk 10 m

80 mg/kg/day ataluren

D52.4
14.0

12.4

15.4

D53.2

D53.0

Comparison of change from baseline to week 48 between ataluren and placebo, mean (95% CI)
40 mg/kg/day ataluren vs Placebo
Climb 4 stairs
Descend 4 stairs
Run/walk 10 m
Supine to stand

22.4
21.6
21.4
20.0

(24.8,
(24.2,
(23.7,
(22.5,

0.0)
1.0)
0.9)
2.4)

80 mg/kg/day ataluren vs Placebo
21.3
21.1
20.7
20.2

(24.0,
(23.9,
(23.0,
(22.6,

1.4)
1.7)
1.7)
2.2)

*For timed function tests, negative differences between ataluren and placebo represent better outcomes in ataluren-treated patients.
CI, confidence interval; Corrected ITT, corrected intent-to-treat population.

Based on an analysis of patients with pre- and
posttreatment muscle biopsy samples, a mean
change from pretreatment to posttreatment of
2.8% in dystrophin/spectrin ratio was observed in
the ataluren 40 mg/kg/day dose group: 1.3% in
the ataluren 80 mg/kg/day dose group and 0.09%
in the placebo group. The method used and
results are further detailed in the Supplementary
Appendix.
Exposure-Response. The inverse dose-response
observed with ataluren was evaluated further by
means of assessment of exposure-response using
ataluren C2h (plasma concentration 2 h postmorning dose), which correlates with ataluren area
under the concentration-time curve (Supplemen-

tary Appendix). In patients who received ataluren
40 mg/kg/day, mean C2h across all visits ranged
between 3.4 and 19.2 mg/ml. In patients who
received ataluren 80 mg/kg/day, mean C2h ranged
between 6.5 and 42.1 mg/ml. Approximately 40%
of 80 mg/kg/day patients had a mean C2h that
overlapped with the range observed in 40 mg/kg/
day patients (<19.3 mg/ml). This cutoff point was
used to analyze changes in 6MWD and timed function tests by dividing the higher-dose arm into lowconcentration
(<19.3
mg/ml)
and
highconcentration (19.3 mg/ml) groups. This allowed
assessment of whether patients who received
80 mg/kg/day, but with exposure in the range of
40 mg/kg/day, performed better than patients
with higher exposure. Consistent with the inverse
dose-response relationship, less mean decline in
6MWD and better performance of timed function
tests was seen in the group of high-dose patients
with mean C2h <19.3 mg/ml (Figure 7).
We also performed an exposure-response analysis by performing a step-wise scan across the entire
ataluren plasma concentration range (see Fig. 8).
P-values for the concentration cuts within the
range of exposure for the 40 mg/kg/day dose are
significant statistically, whereas the P-values for
exposures outside that range (i.e., the high exposure range of the 80 mg/kg/day dose) are not.
DISCUSSION

FIGURE 6. Timed function tests change from baseline to week
48 in Study 007 overall population versus decline-phase
subgroup.
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Before this study, there was no accepted primary endpoint identified as suitable for evaluating
efficacy in clinical trials of patients with
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FIGURE 7. Mean change in 6MWD and timed function tests by
concentration.

dystrophinopathy. The major goal of intervention
during the ambulatory phase of dystrophinopathy
is to maintain walking ability for as long as possible.40 The 6MWT, a standardized assessment of
ambulation,41 had been used to evaluate efficacy
in various diseases,31,32 including myotonic dystrophy type 1.42 An observational study showed that
the 6MWT is feasible and reliable in dystrophinopathy.27 Subsequent studies have further established
the 6MWT as a clinically meaningful outcome measure in dystrophinopathy, and natural history studies show that patients increase in walking ability in
the early years, stabilize, then enter a decline
phase, which leads, potentially rapidly, to complete
loss of ambulation.28,43,44
The results from this Phase 2b study showed
that ataluren at a dose of 40 mg/kg/day demonstrated clinical benefit and a favorable clinical benefit/risk profile in ambulatory patients 5 years old
with dystrophinopathy due to a nonsense mutation.
This study was planned in collaboration with regulatory authorities and academic investigators, and the
design and results of this trial lay the groundwork
for future clinical trials in dystrophinopathy.
The results showed that ataluren 40 mg/kg/
day slowed the rate of decline of walking ability
and achieved the targeted mean 30-meter difference between ataluren and placebo in 6MWD over
48 weeks. No effect was observed in the 80 mg/
kg/day dose. The 30-meter target was based upon
6MWD data from registration-directed studies for
other drugs in other diseases with neuromuscular
manifestations.31,32,42 Differences in mean change
in 6MWD between active and placebo ranged from
28 to 44 meters in these previous studies.
Several lines of evidence support the clinical
meaningfulness of a 30-meter difference in 6MWT.
These include: (1) 2 distribution-based methods
show that a 28.5 to 31.7 meters difference in
6MWD should be considered the minimal clinically
important difference (MCID), and it is clinically
484
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relevant for nmDMD patients.26 Although not statistically significant, patients treated with ataluren
40 mg/kg/day demonstrated a 31.3-meter difference in change in 6MWD relative to placebo. (2)
A 30-meter improvement over placebo in the
6MWT is in the range in which other drugs have
been approved in multiple inherited conditions,
including mucopolysaccharidosis and Pompe disease. (3) Evidence of the clinical relevance of these
results comes from a recent report which showed
that a 30-meter change in 6MWD over 48 weeks
was considered a clinically meaningful change
based on the patient/parent-reported Pediatric
Outcomes Data Collection Instruction (PODCI), a
quality of life measure, in DMD patients with disease status45 similar to this study. (4) Recent
results of longitudinal 6MWT natural history data
in DMD demonstrate that each 30-meter decrease
in baseline 6MWD predicts increasing risk of loss
of ambulation over the following 2 years (Eugenio
Mercuri, MD, unpublished data adapted from a
longitudinal multicentric cohort study46).
Consistent with ataluren’s activity in DMD
patients, a time-to-event analysis of the 6MWT
showed that ataluren-treated patients were less
likely to lose walking ability, defined as a 10%
reduction in 6MWD from baseline. This analysis
showed that ataluren 40 mg/kg/day substantially
slowed disease progression in nmDMD patients.
The separation between ataluren and placebo
occurred early in the study and continued to the
end of the study; by Week 48, 74% of patients who
received ataluren 40 mg/kg/day did not experience disease progression versus 56% of patients
who received placebo (P 5 0.0386; see Fig. 2).
Delaying ambulatory decline provides the direct
clinical benefit of affording boys with nmDMD a
longer period of self-sufficiency. Importantly, slowing the loss of walking ability may also have beneficial effects that could not be measured within a 48-

FIGURE 8. Difference in change from baseline and statistical
significance by concentration. Note: Shaded area represents
exposure range for 40 mg/kg/day ataluren.
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week timeframe. For example, maintenance of
ambulatory capacity has been associated with prevention or delay of onset and reduced severity of
scoliosis and the need for major surgery.47,48
The variability of the 6MWT over 48 weeks in
this disease was unknown at the time the study was
designed. By Week 48, however, it was evident that
there was considerable heterogeneity in the rate of
disease progression in nmDMD. This contributed
to the higher-than-anticipated standard deviation
ranging from 72–90 meters (see Supplementary
Table 1).
Within all subgroups created by the stratification factors, ataluren 40 mg/kg/day treated
patients performed better than placebo patients.
This was true for subgroups based on age, baseline
6MWD, and glucocorticoid use. Clinically meaningful differences in disease progression due to ataluren treatment were also found in both the declinephase subgroup, which included patients aged >7,
on steroids, and baseline values of 6MWD from
150 meters to 80% predicted (D 6MWD 5 49.9
meters), and in the prespecified subgroup with
baseline 6MWD < 350 meters (D 6MWD 5 68.2
meters). These treatment effects over a 48-week
study duration in a placebo-controlled trial of
DMD are substantial, clinically meaningful, and
unprecedented in a corticosteroid-treated population of boys with DMD. The minimal decline in
6MWD among placebo-treated patients with baseline 6MWD 350 meters (D 6MWD 5 29 meters)
indicates that these patients are in a more stable
phase of the disease.
Timed function tests (TFTs) are well-established
and sensitive to changes in disease status.43,44,49,50
Over 48 weeks, ataluren-treated patients showed less
decline in TFTs than placebo. More recent data
have shown that TFTs are important endpoints,
and, like the 6MWT, are predictive of the time for a
patient to become nonambulatory.26 Natural history
data from the Cooperative International Neuromuscular Group (CINRG) and from Study 007 show
that a >6-s time to climb 4 stairs is predictive of a
greater likelihood of 10% progression in the
6MWD, whereas a >8-s stair climb predicts greater
likelihood of loss of ambulation over 1 year.26 The
methods used by patients to perform these tests
were evaluated by means of functional method
grading, which was a novel assessment introduced
in this study. It consisted of a 6-point scale that
assessed functional ability independently for each
timed function test (the complete methodology is
detailed in the Supplementary Appendix).
Patients treated with ataluren 40 mg/kg/day
trended toward less decline in muscle function
compared with placebo as measured by TFTs. The
results were not statistically significant, but they
Ataluren for Dystrophinopathy

met the threshold for clinically meaningful differences, supporting the primary endpoint results.
Among the TFTs, the largest effect for ataluren
40 mg/kg/day was seen in stair-climbing, which is
one of the most difficult activities of daily living
for patients with DMD.51 These data are particularly important, given that Mazzone et al. have
reported that the 6MWT and TFTs provide complementary information and should be used in
combination in dystrophinopathy clinical trials.43
Positive trends favoring ataluren 40 mg/kg/day
versus placebo were also seen for accidental fall
frequency, functional method grading, activity and
wheelchair use in the community setting, myometry, and patient-reported physical functioning. The
consistency of these findings supports an ataluren
40 mg/kg/day treatment effect on physical functioning in ambulatory patients with nmDMD.
The lack of effect on 6MWD at 80 mg/kg/day
is consistent with nonclinical data and the
exposure-response analysis. A bell-shaped concentration-response curve for production of dystrophin has been observed in cultured myotubes
isolated from mdx mice2 and from patients with
nmDMD when they were exposed to ataluren.22
Consistent with these findings, recently published
results showed that ataluren promoted readthrough of a nonsense mutation in the dystrophin
gene of a zebrafish DMD model.52 A bell-shaped
dose-response relationship of ataluren activity in
promoting dystrophin expression was also
observed, consistent with the bell-shaped dose
response curve observed in human and mouse
myotubes.
In the current study, an analysis of 6MWD and
timed function tests by ataluren C2h showed that
ataluren 80 mg/kg/day patients with lower concentrations (i.e., those in the range observed with
the 40 mg/kg/day dose) experienced better outcomes than those patients with higher concentrations (Fig. 7; see Supplementary Appendix for
further details). A bell-shaped exposure-response
relationship has also been seen with aminoglycoside antibiotics (e.g., gentamicin) and other compounds evaluated for their ability to promote
readthrough of premature stop codons.53–55
The dystrophin expression results were difficult
to interpret due to generally poor sample quality
as determined by the central laboratory pathologist, including freezing artifact, orientation, and
fibrotic replacement (See Supplementary Appendix). Furthermore, a sensitive and reliable method
for quantifying dystrophin is not currently available.56 This issue has been recognized in the DMD
research community, where an initiative to develop
and validate a reliable dystrophin quantification
protocol is ongoing.57
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Even though the samples were of poor quality,
all tissue obtained was immunostained for dystrophin and spectrin (used as the control) in a dual
label protocol. A quantitative method for assessing
the ratio of dystrophin/spectrin intensity values
(similar to that used in the Phase 2a proof of concept study22) was used whereby 4 readings per sample were generated and used to produce mean
pre- and posttreatment dystrophin and spectrin
intensity values. A small positive trend was
observed for ataluren compared with placebo.
Ataluren was generally well tolerated at both
dose levels over 48 weeks. Adverse event profiles
were similar in ataluren- and placebo-treated
patients. No patients discontinued from the study
due to an adverse event, and no ataluren-related
serious adverse events were reported.
A lesson learned from this trial is that the study
was underpowered, given the unexpectedly large
standard deviation of the 6MWD scores over 48
weeks. However, the encouraging results of this
double blind, placebo-controlled, long-term study
suggest that ataluren may have a clinically meaningful effect in patients with nonsense mutation
dystrophinopathy. Because dystrophin stabilizes
muscle function but does not build strength, a dystrophin restoration therapy for DMD patients
would be anticipated to preserve muscle function
and delay disease progression. For this reason, in a
48-week trial, the efficacy of ataluren should be
expected to be more notable in patients who have
marked disease progression. The study results confirm this post hoc, as it was demonstrated that ataluren’s effect is most evident in DMD patients with
advanced disease, i.e., patients who have begun a
phase of decline in their ambulatory ability.
Collectively, these data indicate that ataluren
has clinical activity and a favorable safety profile.
There is currently a lack of other diseasemodifying treatment options for patients with nonsense mutations. As the first investigational new
drug to address the underlying cause of dystrophinopathy, ataluren represents an important
advance in personalized, genetic-based treatment
of nonsense mutation disease.
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